Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia 10Recurrence 9Lymphoproliferative Disorders 6Neoplasm, Residual 5Lymphatic Diseases 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Immunoproliferative Disorders 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Lymphoid 2Bites and Stings 2Neoplasms by Histologic Type 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Blast Crisis 1

Interventions

Rituximab 43Cyclophosphamide 26fludarabine 15ibrutinib 14Vincristine 11Prednisone 11Doxorubicin 11pirtobrutinib 10Bendamustine Hydrochloride 10obinutuzumab 9polatuzumab vedotin 6Inotuzumab Ozogamicin 6tocilizumab 5pembrolizumab 5glofitamab 5Gemcitabine 5zanubrutinib 4venetoclax 4ublituximab 4Lenalidomide 4Brentuximab Vedotin 4Antigens, CD19 4tazemetostat 3acalabrutinib 3Everolimus 3DTRMWXHS-12 3veltuzumab 2sepantronium 2iberdomide 2denileukin diftitox 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell × blinatumomab × Clear all
NCT02910063 2021-01-13

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

Amgen

Phase 2/3 Completed
41 enrolled 18 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Lymphoma, B-Cell

NCT00538096 2008-09-05

A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma

MedImmune LLC

Phase 1 Withdrawn
18 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡